Funder
Neutec Ar-Ge San & Tic A.S. (Turkey).
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference37 articles.
1. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.
2. Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, et al. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD. Int J Chron Obstruct Pulmon Dis. 2016;12:13–25.
3. Lewis A, Torvinen S, Dekhuijzen PNR, Chrystyn H, Melani A, Zöllner Y, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017;129:179–88.
4. Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. Int J Chron Obstruct Pulmon Dis. 2016;11:2749–55.
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. Available from:
http://goldcopd.org/global-strategy-diagnosis-managementprevention-copd-2016/
. Accessed 18 Apr 2016.